Moderna, Inc. Furnishes Pipeline Progress and Business Strategy Updates
Summary
Moderna, Inc. (NASDAQ:MRNA) announced program and financial updates at its Analyst Day on November 20, 2025, via an Ex. 99.1 press release. The company unveiled a three-year business strategy targeting up to 10% revenue growth in 2026 and aiming for cash breakeven in 2028. It expects to expand its seasonal vaccine franchise to up to six approved products by 2028. Additionally, Moderna anticipates readouts from nine ongoing Phase 2 and Phase 3 oncology clinical studies, including three Phase 3 programs for intismeran autogene. The company also improved its 2026 and 2027 expected GAAP operating expenses by approximately $0.5 billion each year.
Why It Matters
This update is material as it provides specific financial targets, including up to 10% revenue growth in 2026 and a path to cash breakeven by 2028, alongside significant reductions in operating expenses. Investors should note the strategic focus on expanding the seasonal vaccine franchise and advancing the oncology pipeline, which are key drivers for future growth and profitability.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how MRNA traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View MRNA Charts on TradingViewAffiliate link
Filing Details
Reported Items
Additional Information
- CIK Number
- 0001682852
- Filing Date
- Thursday, November 20, 2025
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive